BTdCPU is an activator of HRI. The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. Combination therapy with rapamycin, an mTOR inhibitor, and BTdCPU, an activator of HRI, demonstrated additive effects on apoptosis in dex-resistant cells. Thus, specific activation of the eIF2α kinase HRI is a novel therapeutic target in MM that can augment current treatment strategies.
Phosphatase Related Products:
KLH45; Voclosporin; Cyclosporin A; Tacrolimus; GSK 2830371; SF1670; BCI-215; L-p-Bromotetramisole oxalate; Salubrinal